Clinical remission · Patients with chronic pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · Patients with chronic pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of clinical remission · Patients with chronic pouchitis
It is very uncertain whether glutamine changes maintenance of clinical remission compared with butyrate (very low certainty).
1 finding from 1 review
No episodes of acute pouchitis · Patients with chronic pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with chronic pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infectious complications · critically ill patients or receiving major surgery
Glutamine‐supplemented nutrition probably leads to lower infectious complications compared with non‐supplemented nutrition (moderate certainty).
1 finding from 1 review
Short‐term mortality (within hospital stay or closest to one month) · critically ill patients or receiving major surgery
Glutamine‐supplemented nutrition showed no clear difference in short‐term mortality (within hospital stay or closest to one month) compared with non‐supplemented nutrition (low certainty).
1 finding from 1 review
Long‐term mortality (closest to six month) · critically ill patients or receiving major surgery
Glutamine‐supplemented nutrition showed no clear difference in long‐term mortality (closest to six month) compared with non‐supplemented nutrition (moderate certainty).
1 finding from 1 review
Length of hospital stay · critically ill patients or receiving major surgery
1 finding from 1 review
Duration of ICU stay · critically ill patients or receiving major surgery
1 finding from 1 review
Duration of mechanical ventilation · critically ill patients or receiving major surgery
1 finding from 1 review
Serious adverse events · critically ill patients or receiving major surgery
Glutamine‐supplemented nutrition showed no clear difference in serious adverse events compared with non‐supplemented nutrition (moderate certainty).
1 finding from 1 review
Mean GI symptom scores · People undergoing RT for pelvic cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute and late GI toxicity (grade 2+) · People undergoing RT for pelvic cancer
Summary of findings: Glutamine showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea (grade 2+) · People undergoing RT for pelvic cancer
Summary of findings: Glutamine showed no clear difference in diarrhoea (grade 2+) compared with placebo (high certainty).
1 finding from 1 review
QoL · People undergoing RT for pelvic cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes incidence of hepatic veno‐occlusive disease ( compared with placebo (very low certainty).
1 finding from 1 review
Overall survival · People undergoing stem cell transplant with haematological malignancies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes all‐cause mortality at 100 days post‐transplant ( compared with placebo (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo (very low certainty).
1 finding from 1 review